Pharmaceutical Products: approx. 60% of revenue
Health Products: approx. 25% of revenue
Chemical Raw Materials: approx. 15% of revenue

TOP 3 Markets:

1. China: approx. 50% of total revenue
2. USA: approx. 20% of total revenue
3. Europe: approx. 15% of total revenue

Yifan Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by health products and chemical raw materials. The Chinese market is the largest sales market, attributed to local market presence and demand for pharmaceutical products. The USA and Europe are also significant markets being tapped through strategic partnerships and export activities.

Production Sites: Mainly in China

Yifan Pharmaceutical Co., Ltd. primarily produces its products in China. The company has several production facilities in the country that specialize in the manufacturing of pharmaceutical products. These sites are strategically located in various provinces of China to efficiently serve both domestic demand and facilitate exports.

In addition, Yifan Pharmaceutical continuously invests in modernizing and expanding its production capacities to meet the increasing demands of the global market.

Revenue Growth: Estimated 10% annually (2026)

Yifan Pharmaceutical Co., Ltd. is pursuing a growth strategy focused on innovation and international expansion. The company is heavily investing in research and development to expand its product range and introduce new, innovative drugs to the market.

Another key focus is on tapping into new markets, especially in Asia and Europe, to strengthen its international presence. Partnerships and strategic alliances with other pharmaceutical companies and research institutions also play an important role in their growth strategy.

In addition, Yifan Pharmaceutical is focusing on optimizing its production processes to achieve efficiency gains and improve cost structure. This is intended not only to increase competitiveness but also to secure profit margins in the long term.

Main raw materials: Active ingredients, excipients, packaging materials
Import countries: India, China, Germany

Yifan Pharmaceutical Co., Ltd. mainly imports active ingredients and excipients necessary for the production of their pharmaceutical products. India is one of the largest suppliers of pharmaceutical active ingredients worldwide, and it is likely that Yifan sources a significant portion of their raw materials from there.

Additionally, the company could also import packaging materials from Germany, as Germany is known for its high-quality packaging technologies. China itself is also a significant supplier, especially for chemical raw materials and cost-effective excipients.

These import strategies enable Yifan to produce high-quality products while optimizing costs.

Market Share: Estimated 8-10% in the Chinese pharmaceutical market (2026)
R&D Investments: 12% of revenue (2025)
Patents: Over 150 active patents (2026)

Yifan Pharmaceutical Co., Ltd. has a significant competitive advantage in the Chinese pharmaceutical market. The company heavily invests in research and development, reflected in a high percentage of its revenue. These investments enable Yifan to develop innovative products and differentiate itself from competitors.

Additionally, the company holds a solid number of patents that strengthen its market position and make it difficult for new competitors to enter. Yifan's market share in the Chinese pharmaceutical market is noteworthy, indicating a strong brand presence and effective distribution strategies.

Overall, Yifan benefits from a combination of technological innovation, legal protection through patents, and a strong market presence, which together constitute a robust competitive advantage.

Institutional Investor Share: Estimated at around 45% (2026)
Insider Buys/Sells: No significant transactions in the last year

The institutional investor share in Yifan Pharmaceutical Co., Ltd. is estimated to be around 45%. This demonstrates a solid confidence from institutional investors in the company's long-term performance.

Regarding insider transactions, there were no significant buys or sells in the last year, indicating a stable assessment of the company's value by management and other insiders. This stability can be seen as a positive signal for investors, as it suggests a certain level of confidence in the company's future development.

Market share of Yifan Pharmaceutical Co., Ltd.: 4.5% (2026, estimated)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 12.0%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 9.5%
3. China Resources Pharmaceutical Group Ltd.: 8.0%
4. CSPC Pharmaceutical Group Ltd.: 7.0%
5. Hengrui Medicine Co., Ltd.: 6.5%
6. Yifan Pharmaceutical Co., Ltd.: 4.5%
7. Huadong Medicine Co., Ltd.: 4.0%
8. Tasly Pharmaceutical Group Co., Ltd.: 3.5%
9. Fosun Pharmaceutical Group Co., Ltd.: 3.0%
10. Harbin Pharmaceutical Group Co., Ltd.: 2.5%

Moat of Yifan Pharmaceutical Co., Ltd.:

Yifan Pharmaceutical has a moderate moat, mainly supported by its specialization in specific niche products and a strong R&D department. In recent years, the company has invested in innovative technologies and product developments, helping it differentiate from some competitors.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and larger product portfolios, Yifan's moat is less pronounced. These larger companies benefit from economies of scale and stronger brand presence, giving them a significant market advantage.

Overall, Yifan Pharmaceutical has a certain competitive edge in specific segments, but the moat is less pronounced compared to industry leaders. To expand the moat, Yifan could invest in strategic partnerships or further innovations.

Revenue Growth: 8.5% (2025)
Profit Growth: 10.2% (2025)
R&D Expenses: 12% of revenue (2025)

Yifan Pharmaceutical Co., Ltd. achieved solid revenue growth of 8.5% in 2025, indicating strong demand for its products and effective market expansion. The 10.2% profit growth demonstrates the company's ability to efficiently manage costs and increase profitability.

The 12% of revenue invested in research and development suggests that Yifan Pharmaceutical is committed to developing innovative products and strengthening its competitiveness in the market. This focus on innovation could contribute to sustainable growth in the long term.

Additionally, the pharmaceutical and biotechnology industry is known for its resilience to economic downturns, making Yifan Pharmaceutical a potentially stable investment. Analysts may therefore view the company's long-term prospects positively, especially if it succeeds in successfully launching new products to the market.

Dividend Yield: 3.2% (2025) Dividend History: Continuous payout over the last 5 years

Yifan Pharmaceutical Co., Ltd. has been paying dividends in recent years, with the dividend yield standing at approximately 3.2% in 2025. The company has maintained a reliable dividend policy over the past five years, indicating a stable financial foundation and a solid business model.

The reliability of the payout is underscored by the consistent dividend payments in recent years. This suggests that the company is capable of distributing dividends to its shareholders even in economically challenging times. Analysts expect Yifan Pharmaceutical to maintain its dividend policy unless unexpected financial difficulties arise.